$COR

Cencora, Inc.

Cencora distributes pharmaceuticals and related healthcare products and services to healthcare providers and pharmaceutical and biotech manufacturers in the United States and select global markets. Its two reportable segments are U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. segment supplies brand-name, specialty and generic drugs, over-the-counter products, home healthcare supplies and equipment, and services to hospitals, pharmacies, clinics, physicians and veterinarians. It also sells animal health products and offers pharmacy management, consulting, staffing, software and packaging services. The international segment distributes pharmaceuticals and healthcare products, provides specialty transportation and logistics for the biopharmaceutical industry, and offers life sciences services such as regulatory affairs and pharmacovigilance. Cencora also provides data analytics, reimbursement and market access support, inventory management, pharmacy automation and commercialization services. It makes money through the distribution and sale of products and by providing related services to healthcare providers and manufacturers. Its headquarters are in Conshohocken, Pennsylvania.

1
0
2
—
$326K
Krikorian Lazarus
100%
See all $COR insider activity →
Low

Wells Fargo raises Cencora stock price target to $400 on estimates

Wells Fargo raised its price target for Cencora (NYSE:COR) to $400, citing an 18x multiple on 2028 EPS. The firm adjusted EPS estimates slightly downward for 2027 and 2028. Cencora's Q4 results beat expectations, with EPS of $4.66 and revenue of $88.4B, driven by specialty pharmaceutical demand and acquisitions. The stock trades at a P/E of 19.87 and PEG of 0.16, suggesting potential undervaluation.

COR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning COR (Cencora, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.

Recent COR coverage spans financial news, earnings and corporate actions.

In the last 30 days, COR insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($326K). The most active reporter was Krikorian Lazarus, SVP & Chief Accounting Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving COR

  • Street valuation support via a higher PT, but EPS estimate trims and unchanged valuation multiple suggest a modest, not transformative, catalyst.

    investing.com · Nov 17, 2026

  • Deal blockage could hurt Cencora's valuation of the divestiture.

    seekingalpha.com · Nov 13, 2026

  • JP Morgan kept Cencora's rating at Overweight and increased its price target to $413 from $390, suggesting a 19.4% upside from the Nov 9 close of $345.76. Recent analyst price targets for Cencora range from $375 to $405.

    tradingview.com · Nov 10, 2026

  • Leerink Partners kept its Outperform rating on Cencora and increased its price target to $405 from $388, suggesting a 14.4% upside from the Nov 4 close of $354. Recent analyst targets for Cencora range from $375 to $400.

    tradingview.com · Nov 5, 2026

  • Evercore ISI Group kept its Outperform rating on Cencora and raised its price target to $380 from $350, citing an 8.6% increase. The new target implies a 7.3% upside from Cencora's Nov 4 close of $354. Recent analyst notes on Cencora have price targets ranging from $375 to $400.

    tradingview.com · Nov 5, 2026

AlphAI scores every news story that mentions COR with an AI model for sentiment and relevance, and aggregates insider trades from Cencora, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $COR

Score

Wells Fargo raises Cencora stock price target to $400 on estimates

Wells Fargo raised its price target for Cencora (NYSE:COR) to $400, citing an 18x multiple on 2028 EPS. The firm adjusted EPS estimates slightly downward for 2027 and 2028. Cencora's Q4 results beat expectations, with EPS of $4.66 and revenue of $88.4B, driven by specialty pharmaceutical demand and acquisitions. The stock trades at a P/E of 19.87 and PEG of 0.16, suggesting potential undervaluation.

Cencora, Inc. (COR): Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year (As Revised) (As Revised)

Cencora, Inc. (COR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CENCORA, INC. SUMMARY REPORTABLE SEGMENT INFORMATION (in thousands) (unaudited) The following illustrates revised reportable segment revenue information for the periods indicated: Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter

$CORHighAI 8/10Earnings

CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS Fourth Quarter Revenue of $88.4 Billion up 5.5 Percent. GAAP Diluted EPS of $2.71 and Adjusted Diluted EPS of $4.66 Fiscal Year 2026 Revenue of $337.4 Billion up 5.0 Percent. GAAP Diluted EPS of $

Is Cencora (COR) Fully Valued Following Its $2.4b American Oncology Network Deal?

Cencora (COR) is expanding in specialty pharmaceuticals, with platforms like OneOncology exceeding expectations. The company completed a $1.0b share buyback in Q3 2026 at $268 per share and authorized an additional $2.0b for repurchases, aiming to reduce share count and boost earnings per share. According to the article, this positions Cencora for continued growth in higher-margin services.

Related tickers